Showing 321-330 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Targeted delivery of therapeutics to islet beta cells for preventing and treating diabetes | UT Southwestern | Juanzhu Yan | Cures | 01-March-2025 to 30-April-2028 | $285,000.00 |
| Immune-checkpoint engineered beta cells as treatment for T1D | UT Southwestern | Andrew Wang | Cures | 01-October-2023 to 30-September-2026 | $746,818.40 |
| Development of Allosteric G6PC1 Partial Inhibitors | Vanderbilt University | Richard O’Brien | Improving Lives | 01-October-2023 to 31-October-2026 | $549,940.00 |
| Targeting the CERS2-Sphingolipid Axis to Protect Human Beta-Cells in T1D | Vanderbilt University | Katie Coate | Cures | 01-May-2026 to 30-April-2027 | $199,979.61 |
| Investigation of AKS-107 immunotherapeutic in mice and human cells | Vanderbilt University Medical Center (VUMC) | Rachel Bonami | Cures | 01-July-2024 to 30-June-2027 | $800,000.00 |
| Targeting the Autoimmune Germinal Center Axis in Type 1 Diabetes | Vanderbilt University Medical Center (VUMC) | Rachel Bonami | Cures | 01-March-2026 to 29-February-2028 | $600,000.00 |
| Bcl6 and the B/Tfh axis in type 1 diabetes pathogenesis | Vanderbilt University Medical Center (VUMC) | Dudley McNitt | Cures | 01-March-2024 to 28-February-2027 | $264,964.50 |
| B cell-Treg interactions in immune therapy for T1D | Vanderbilt University Medical Center (VUMC) | Daniel Moore | Cures | 01-March-2026 to 28-February-2029 | $660,000.00 |
| Determination of autoreactive B lymphocyte development by ROS in T1D | Vanderbilt University Medical Center (VUMC) | Christopher Wilson | Cures | 01-July-2023 to 30-June-2026 | $211,157.03 |
| Developing Fit-For-Purpose Patient-reported Outcomes (PRO) Measure(s) in Type 1 Diabetes | Vector Psychometric Group | R. J. Wirth | Cures | 01-February-2025 to 30-June-2027 | $836,157.00 |